Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World
Cette étude analyse, dans plusieurs pays européens (Angleterre, France, Allemagne, Pays-Bas, Ecosse, Pologne), les modalités d'évaluation des médicaments en oncologie pour définir leur prix ou leur remboursement
The current system of drug pricing and reimbursement in the United States (U.S.) is under intense scrutiny. Much has been written about perverse incentives and legislation [1, 2] that have led to an exponential increase in drug prices [3], with U.S. prices being significantly higher than those in the rest of the world[4].The U.S.now needs to look to the rest of the world to understand how to best understand how to best improve its pricing and reimbursement system. In this article, we will describe drug pricing and reimbursement mechanisms used in other countries to understand the features of an optimal system